SecBot SecBot
SECBOTREPLAY Home › Report › ABEO

ABEO · Abeona Therapeutics reported its first full year of commercial…

Abeona Therapeutics Inc. · PRESS-RELEASE filed Mar 17, 2026 at 07:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 17, 2026 at 07:30 ET

Abeona Therapeutics reported its first full year of commercial operations following FDA approval of ZEVASKYN, with $5.8 million in revenue and a net income of $71.2 million in 2025, driven primarily by a $152.4 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher. The company treated its first commercial patient in December 2025 and has expanded its Qualified Treatment Center network, signaling early commercial traction for its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

  • First commercial patient treated with ZEVASKYN in December 2025; one additional patient treated in Q1 2026.
  • Total revenue for 2025 was $5.82 million, including $2.42 million in net product revenue from one patient and $3.4 million in license revenue.
  • Gain from sale of Priority Review Voucher (PRV) contributed $152.4 million to net income, which totaled $71.2 million for 2025 (vs. $63.7 million net loss in 2024).
  • Cash, cash equivalents, and short-term investments totaled $191.4 million as of December 31, 2025.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access